Literature DB >> 10942175

Ketobemidone may alter busulfan pharmacokinetics during high-dose therapy.

M Hassan1, J O Svensson, C Nilsson, P Hentschke, A Al-Shurbaji, J Aschan, P Ljungman, O Ringdén.   

Abstract

The authors report a possible interaction between ketobemidone and busulfan during myeloablative treatment of a patient with acute myeloid leukemia. At the time of admission, the patient was receiving ketobemidone 1,000 mg/d as analgesic for a rectal fissure. The patient started conditioning prior to bone marrow transplantation with busulfan (1 mg/kg x 4 for 4 days). High busulfan plasma concentrations were observed after the first dose and the next doses were reduced to 0.7 mg/kg. The kinetics of both drugs revealed that an increase in ketobemidone concentration was followed by an increase in busulfan levels. Substituting ketobemidone with morphine resulted in a decrease in busulfan concentration despite increasing the dose once more to 1 mg/kg.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10942175     DOI: 10.1097/00007691-200008000-00003

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  6 in total

Review 1.  Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients.

Authors:  Rachael Lawson; Christine E Staatz; Christopher J Fraser; Stefanie Hennig
Journal:  Clin Pharmacokinet       Date:  2020-10-30       Impact factor: 6.447

2.  Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients.

Authors:  Christa E Nath; John W Earl; Nalini Pati; Katherine Stephen; Peter J Shaw
Journal:  Br J Clin Pharmacol       Date:  2008-03-13       Impact factor: 4.335

Review 3.  Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review.

Authors:  Alan L Myers; Jitesh D Kawedia; Richard E Champlin; Mark A Kramer; Yago Nieto; Romi Ghose; Borje S Andersson
Journal:  Expert Opin Drug Metab Toxicol       Date:  2017-08-17       Impact factor: 4.481

4.  Flavin-containing monooxygenase 3 (FMO3) role in busulphan metabolic pathway.

Authors:  Ibrahim El-Serafi; Ylva Terelius; Manuchehr Abedi-Valugerdi; Seán Naughton; Maryam Saghafian; Ali Moshfegh; Jonas Mattsson; Zuzana Potácová; Moustapha Hassan
Journal:  PLoS One       Date:  2017-11-09       Impact factor: 3.240

5.  Pharmacometabolomics for predicting variable busulfan exposure in paediatric haematopoietic stem cell transplantation patients.

Authors:  Bora Kim; Ji Won Lee; Kyung Taek Hong; Kyung-Sang Yu; In-Jin Jang; Kyung Duk Park; Hee Young Shin; Hyo Seop Ahn; Joo-Youn Cho; Hyoung Jin Kang
Journal:  Sci Rep       Date:  2017-05-10       Impact factor: 4.379

6.  Vitamin D levels and busulphan kinetics in patients undergoing hematopoietic stem cell transplantation, a multicenter study.

Authors:  Ahmed El-Serafi; Rui He; Wenyi Zheng; Fadwa Benkossou; Sandra Oerther; Ying Zhao; Karin Mellgren; Britt Gustafsson; Carsten Heilmann; Jukka Kanerva; Kourosh Lotfi; Jacek Toporski; Mikael Sundin; Martin Höglund; Jonas Mattsson; Ibrahim El-Serafi; Moustapha Hassan
Journal:  Bone Marrow Transplant       Date:  2020-10-21       Impact factor: 5.483

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.